Compare Stocks: FBIO, IKT, VNDA, and TTRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$2.52 -1.9%	$2.99	$2.18 ▼ $4.53	$84.04M	1.19	365,803 shs	209,598 shs
IKT Inhibikase Therapeutics	$2.34 +0.4%	$2.31	$1.33 ▼ $2.61	$326.51M	0.95	379,251 shs	303,243 shs
TTRX Turn Therapeutics	$12.69 -5.2%	$9.71	$2.57 ▼ $26.50	$378.01M	N/A	81,162 shs	135,659 shs
VNDA Vanda Pharmaceuticals	$5.09 +1.0%	$5.42	$4.27 ▼ $9.94	$307.76M	0.64	711,811 shs	698,143 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	0.00%	-7.35%	-15.44%	-9.03%	-34.72%
IKT Inhibikase Therapeutics	0.00%	-6.40%	-2.90%	+40.12%	+51.95%
TTRX Turn Therapeutics	0.00%	+29.49%	+28.70%	+109.75%	+1,268,999,900.00%
VNDA Vanda Pharmaceuticals	0.00%	-6.26%	+1.19%	-13.29%	+13.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$2.52 -1.9%	$2.99	$2.18 ▼ $4.53	$84.04M	1.19	365,803 shs	209,598 shs
IKT Inhibikase Therapeutics	$2.34 +0.4%	$2.31	$1.33 ▼ $2.61	$326.51M	0.95	379,251 shs	303,243 shs
TTRX Turn Therapeutics	$12.69 -5.2%	$9.71	$2.57 ▼ $26.50	$378.01M	N/A	81,162 shs	135,659 shs
VNDA Vanda Pharmaceuticals	$5.09 +1.0%	$5.42	$4.27 ▼ $9.94	$307.76M	0.64	711,811 shs	698,143 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	0.00%	-7.35%	-15.44%	-9.03%	-34.72%
IKT Inhibikase Therapeutics	0.00%	-6.40%	-2.90%	+40.12%	+51.95%
TTRX Turn Therapeutics	0.00%	+29.49%	+28.70%	+109.75%	+1,268,999,900.00%
VNDA Vanda Pharmaceuticals	0.00%	-6.26%	+1.19%	-13.29%	+13.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBIO Fortress Biotech	2.25	Hold	$17.00	574.60% Upside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	130.77% Upside
TTRX Turn Therapeutics	2.50	Moderate Buy	$8.00	-36.96% Downside
VNDA Vanda Pharmaceuticals	2.50	Moderate Buy	$13.70	169.16% Upside

Current Analyst Ratings Breakdown

Latest FBIO, IKT, VNDA, and TTRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/10/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00 ➝ $20.00
8/10/2026	VNDA Vanda Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $12.00
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/21/2026	TTRX Turn Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/20/2026	TTRX Turn Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (D-)
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBIO Fortress Biotech	$63.26M	1.33	N/A	N/A	$2.00 per share	1.26
IKT Inhibikase Therapeutics	$260K	1,255.86	N/A	N/A	$2.30 per share	1.02
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	$0.16 per share	N/A
VNDA Vanda Pharmaceuticals	$216.10M	1.42	N/A	N/A	$5.54 per share	0.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBIO Fortress Biotech	$6.82M	$2.64	0.95	N/A	N/A	163.32%	83.47%	42.98%	11/16/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
TTRX Turn Therapeutics	-$3.19M	-$0.29	N/A	N/A	N/A	N/A	-230.84%	-53.19%	N/A
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)

Latest FBIO, IKT, VNDA, and TTRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million
8/12/2026	Q2 2026	TTRX Turn Therapeutics	N/A	-$0.20	N/A	-$0.20	N/A	N/A
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBIO Fortress Biotech	0.17	3.96	3.83
IKT Inhibikase Therapeutics	N/A	15.82	15.82
TTRX Turn Therapeutics	8.83	1.19	1.19
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBIO Fortress Biotech	96.51%
IKT Inhibikase Therapeutics	3.81%
TTRX Turn Therapeutics	N/A
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
FBIO Fortress Biotech	28.50%
IKT Inhibikase Therapeutics	7.10%
TTRX Turn Therapeutics	N/A
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBIO Fortress Biotech	170	33.35 million	23.85 million	Optionable
IKT Inhibikase Therapeutics	6	139.54 million	129.63 million	N/A
TTRX Turn Therapeutics	2	29.79 million	N/A	N/A
VNDA Vanda Pharmaceuticals	290	60.46 million	53.99 million	Optionable

FBIO, IKT, VNDA, and TTRX Headlines

Recent News About These Companies

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 7, 2026 | marketbeat.com

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

September 2, 2026 | prnewswire.com

BlackRock Inc. Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

September 1, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.32 Million in Vanda Pharmaceuticals Inc. $VNDA

August 31, 2026 | marketbeat.com

Ieq Capital LLC Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

August 26, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA)

August 25, 2026 | finance.yahoo.com

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

August 24, 2026 | prnewswire.com

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

August 22, 2026 | prnewswire.com

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA

August 17, 2026 | marketbeat.com

AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA

August 17, 2026 | marketbeat.com

Vanda (VNDA) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

August 11, 2026 | zacks.com

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Vanda Pharmaceuticals Balances Strong Growth With Rising Losses

August 5, 2026 | tipranks.com

Vanda: Q2 Earnings Snapshot

August 5, 2026 | chron.com

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2026 | zacks.com

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 5, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo Finance

July 29, 2026 | finance.yahoo.com

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

July 29, 2026 | prnewswire.com

Vanda Pharmaceuticals: Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold

July 17, 2026 | seekingalpha.com

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a ...

July 17, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, IKT, VNDA, and TTRX Company Descriptions

Fortress Biotech NASDAQ:FBIO

$2.52 -0.05 (-1.95%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.54 +0.02 (+0.60%)

As of 09/11/2026 07:59 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Inhibikase Therapeutics NASDAQ:IKT

$2.34 +0.01 (+0.43%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.33 -0.01 (-0.43%)

As of 09/11/2026 07:30 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Turn Therapeutics NASDAQ:TTRX

$12.69 -0.69 (-5.16%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.60 -0.08 (-0.67%)

As of 09/11/2026 07:41 PM Eastern

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

Vanda Pharmaceuticals NASDAQ:VNDA

$5.09 +0.05 (+0.99%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.12 +0.03 (+0.49%)

As of 09/11/2026 07:30 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBIO, IKT, VNDA, and TTRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBIO, IKT, VNDA, and TTRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBIO, IKT, VNDA, and TTRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, IKT, VNDA, and TTRX Company Descriptions

Fortress Biotech NASDAQ:FBIO

Inhibikase Therapeutics NASDAQ:IKT

Turn Therapeutics NASDAQ:TTRX

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBIO, IKT, VNDA, and TTRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBIO, IKT, VNDA, and TTRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBIO, IKT, VNDA, and TTRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, IKT, VNDA, and TTRX Company Descriptions

Fortress Biotech NASDAQ:FBIO

Inhibikase Therapeutics NASDAQ:IKT

Turn Therapeutics NASDAQ:TTRX

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools